Trial Profile
A Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Aug 2021
Price :
$35
*
At a glance
- Drugs Gilteritinib (Primary)
- Indications Acute myeloid leukaemia; Solid tumours
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 13 Aug 2020 Status changed from active, no longer recruiting to completed.
- 11 Jun 2020 Planned End Date changed from 1 Jul 2024 to 1 Dec 2020.
- 11 Jun 2020 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2020.